Nautilus Biotechnology Statistics
Share Statistics
Nautilus Biotechnology has 125.56M shares outstanding. The number of shares has increased by 0.35% in one year.
| Shares Outstanding | 125.56M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.12% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 57.49M |
| Failed to Deliver (FTD) Shares | 67 |
| FTD / Avg. Volume | 0.06% |
Short Selling Information
The latest short interest is 1.21M, so 0.97% of the outstanding shares have been sold short.
| Short Interest | 1.21M |
| Short % of Shares Out | 0.97% |
| Short % of Float | 2.11% |
| Short Ratio (days to cover) | 19.69 |
Valuation Ratios
The PE ratio is -5.87 and the forward PE ratio is -3.36.
| PE Ratio | -5.87 |
| Forward PE | -3.36 |
| PS Ratio | 0 |
| Forward PS | 23.1 |
| PB Ratio | 1.41 |
| P/FCF Ratio | -6.9 |
| PEG Ratio | n/a |
Enterprise Valuation
Nautilus Biotechnology Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 19.39, with a Debt / Equity ratio of 0.01.
| Current Ratio | 19.39 |
| Quick Ratio | 19.39 |
| Debt / Equity | 0.01 |
| Total Debt / Capitalization | 1.32 |
| Cash Flow / Debt | -14.62 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.24% and return on capital (ROIC) is -25.39%.
| Return on Equity (ROE) | -0.24% |
| Return on Assets (ROA) | -0.21% |
| Return on Capital (ROIC) | -25.39% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -395.50K |
| Employee Count | 161 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -38.36% in the last 52 weeks. The beta is 1.04, so Nautilus Biotechnology 's price volatility has been higher than the market average.
| Beta | 1.04 |
| 52-Week Price Change | -38.36% |
| 50-Day Moving Average | 2.52 |
| 200-Day Moving Average | 2.59 |
| Relative Strength Index (RSI) | 38.28 |
| Average Volume (20 Days) | 108.90K |
Income Statement
In the last 12 months, Nautilus Biotechnology had revenue of $0 and earned -$63.67M in profits. Earnings per share was $-0.51.
| Revenue | 0 |
| Gross Profit | -5.71M |
| Operating Income | -76.15M |
| Net Income | -63.67M |
| EBITDA | -74.30M |
| EBIT | - |
| Earnings Per Share (EPS) | -0.51 |
Balance Sheet
The company has $19.40M in cash and $34.63M in debt, giving a net cash position of -$15.23M.
| Cash & Cash Equivalents | 19.40M |
| Total Debt | 34.63M |
| Net Cash | -15.23M |
| Retained Earnings | -202.24M |
| Total Assets | 259.70M |
| Working Capital | 135.54M |
Cash Flow
In the last 12 months, operating cash flow was -$51.71M and capital expenditures -$2.44M, giving a free cash flow of -$54.15M.
| Operating Cash Flow | -51.71M |
| Capital Expenditures | -2.44M |
| Free Cash Flow | -54.15M |
| FCF Per Share | -0.43 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
NAUT does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -26.02% |
| FCF Yield | -22.01% |
Analyst Forecast
The average price target for NAUT is $3, which is 53.1% higher than the current price. The consensus rating is "Sell".
| Price Target | $3 |
| Price Target Difference | 53.1% |
| Analyst Consensus | Sell |
| Analyst Count | 3 |
Scores
| Altman Z-Score | 2.48 |
| Piotroski F-Score | 2 |